Aslam Amod

1.6k total citations · 1 hit paper
28 papers, 798 citations indexed

About

Aslam Amod is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Aslam Amod has authored 28 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Aslam Amod's work include Diabetes Treatment and Management (17 papers), Diabetes Management and Research (16 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). Aslam Amod is often cited by papers focused on Diabetes Treatment and Management (17 papers), Diabetes Management and Research (16 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). Aslam Amod collaborates with scholars based in South Africa, United Kingdom and United States. Aslam Amod's co-authors include Richard E. Pratley, Michael A. Nauck, Juris J. Meier, Ildiko Lingvay, Søren T. Hoff, Takashi Kadowaki, Trine Saugstrup, Karen Boje Pedersen, Eleanor Gouws and Fraser Pirie and has published in prestigious journals such as The Lancet, Diabetes Care and Diabetes.

In The Last Decade

Aslam Amod

27 papers receiving 767 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

2019 411 citations Richard E. Pratley, Aslam Amod et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aslam Amod South Africa	12	639	286	170	134	97	28	798
Cesare Berra Italy	16	530 0.8×	249 0.9×	101 0.6×	197 1.5×	116 1.2×	40	860
Francis C. C. Chow Hong Kong	14	765 1.2×	369 1.3×	107 0.6×	247 1.8×	117 1.2×	28	1.1k
Bipin Sethi India	12	952 1.5×	485 1.7×	198 1.2×	313 2.3×	85 0.9×	44	1.2k
Kenneth E. Robertson United States	11	873 1.4×	457 1.6×	180 1.1×	259 1.9×	119 1.2×	14	1.0k
Ioannis Avgerinos Greece	13	901 1.4×	406 1.4×	224 1.3×	276 2.1×	83 0.9×	29	1.1k
Charlotte Hindsberger Denmark	14	480 0.8×	233 0.8×	241 1.4×	248 1.9×	69 0.7×	23	1.0k
Milan Kvapil Czechia	15	399 0.6×	167 0.6×	64 0.4×	188 1.4×	59 0.6×	73	737
Irl B. Hirsch United States	7	746 1.2×	179 0.6×	74 0.4×	206 1.5×	75 0.8×	14	919
Chintan V. Dave United States	11	438 0.7×	146 0.5×	88 0.5×	143 1.1×	52 0.5×	20	618
Nicolae Hâncu Romania	18	696 1.1×	179 0.6×	65 0.4×	221 1.6×	238 2.5×	54	1.1k

Countries citing papers authored by Aslam Amod

Since Specialization

Citations

This map shows the geographic impact of Aslam Amod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aslam Amod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aslam Amod more than expected).

Fields of papers citing papers by Aslam Amod

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aslam Amod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aslam Amod. The network helps show where Aslam Amod may publish in the future.

Co-authorship network of co-authors of Aslam Amod

This figure shows the co-authorship network connecting the top 25 collaborators of Aslam Amod. A scholar is included among the top collaborators of Aslam Amod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aslam Amod. Aslam Amod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khunti, Kamlesh, Francesco Zaccardi, Aslam Amod, et al.. (2024). Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. Diabetologia. 68(1). 17–28. 9 indexed citations

Khunti, Kamlesh, Mussa Almalki, Juliana C.N. Chan, & Aslam Amod. (2023). The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR. Diabetes Therapy. 14(10). 1609–1625. 7 indexed citations

Hassanein, Mohamed, Mostafa Q. Alshamiri, Aslam Amod, et al.. (2022). Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies. Diabetes Therapy. 13(7). 1253–1280. 4 indexed citations

Webb, D. Robert, et al.. (2021). Patterns of diabetes management in South Africa: baseline and 24-month data from the South African cohort of the DISCOVER study. Journal of Endocrinology Metabolism and Diabetes of South Africa. 26(2). 60–65. 4 indexed citations

Amod, Aslam. (2020). The Place of Sulfonylureas in Guidelines: Why Are There Differences?. Diabetes Therapy. 11(S1). 5–14. 12 indexed citations

Khunti, Kamlesh, Mohamed Hassanein, Moon‐Kyu Lee, Viswanathan Mohan, & Aslam Amod. (2020). Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. Diabetes Therapy. 11(S2). 33–48. 22 indexed citations

Desouza, Cyrus, Aslam Amod, Klaus Kallenbach, et al.. (2020). 930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program. Diabetes. 69(Supplement_1). 4 indexed citations

Amod, Aslam, John B. Buse, Darren K. McGuire, et al.. (2019). Glomerular Filtration Rate and Associated Risks ofCardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes:Secondary Analysis (DEVOTE 11). Diabetes Therapy. 11(1). 53–70. 15 indexed citations

Pratley, Richard E., Aslam Amod, Søren T. Hoff, et al.. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet. 394(10192). 39–50. 411 indexed citations breakdown →

10.

Blom, Dirk, et al.. (2019). Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovascular journal of South Africa. 30(1). 15–23. 10 indexed citations

11.

Kaplan, Hilton M., et al.. (2019). Incidence of hypoglycaemia in the South African population with diabetes: results from the IDMPS Wave 7 study. Journal of Endocrinology Metabolism and Diabetes of South Africa. 24(2). 58–64. 4 indexed citations

12.

Amod, Aslam, Scott S. Emerson, Steven P. Marso, et al.. (2018). Chronic Kidney Disease (CKD) and Risk of Mortality, Cardiovascular (CV) Events, and Severe Hypoglycemia in Type 2 Diabetes (T2D)-DEVOTE Results. Diabetes. 67(Supplement_1). 3 indexed citations

13.

Distiller, Larry A., et al.. (2014). A 24-Week, Prospective, Randomized, Open-Label, Treat-To-Target Pilot Study of Obese Type 2 Diabetes Patients with Severe Insulin Resistance to Assess the Addition of Exenatide on the Efficacy of U-500 Regular Insulin Plus Metformin. Endocrine Practice. 20(11). 1143–1150. 13 indexed citations

14.

Amod, Aslam, et al.. (2013). Continuous subcutaneous insulin infusion therapy in type 1 diabetes: 2013 clinical guidelines and recommendations from the Association of Clinical Endocrinologists of South Africa (ACE-SA). Journal of Endocrinology Metabolism and Diabetes of South Africa. 18(1). 15–19. 1 indexed citations

15.

Amod, Aslam. (2012). The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes. Journal of Endocrinology Metabolism and Diabetes of South Africa. 17(1). 61–62. 48 indexed citations

16.

Amod, Aslam, et al.. (2012). Diabetes guidelines and clinical practice: is there a gap? The South African cohort of the International Diabetes Management Practices Study. Journal of Endocrinology Metabolism and Diabetes of South Africa. 17(2). 85–90. 18 indexed citations

17.

Amod, Aslam, et al.. (2010). Meeting of the MindsCommon goals, different viewpoints : cardiologists and endocrinologists face off in a series of stimulating debates. Cardiovascular journal of South Africa. 21(1). 9–13. 1 indexed citations

18.

Amod, Aslam, et al.. (2009). Polycystic ovary syndrome. Journal of Endocrinology Metabolism and Diabetes of South Africa. 14(2). 86–95. 7 indexed citations

19.

Hollander, Priscilla, et al.. (2009). Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial. Diabetes Care. 33(3). 605–607. 39 indexed citations

20.

Motala, Ayesha A., Fraser Pirie, Eleanor Gouws, Aslam Amod, & M. A. K. Omar. (2003). High incidence of Type 2 diabetes mellitus in South African Indians: a 10‐year follow‐up study. Diabetic Medicine. 20(1). 23–30. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact